|By Marketwired .||
|April 23, 2014 04:10 PM EDT|
SAN FRANCISCO, CA and ANN ARBOR, MI -- (Marketwired) -- 04/23/14 -- Medivation, Inc. (NASDAQ: MDVN) and OncoFusion Therapeutics, Inc. today announced that they have entered into a research and license agreement for certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins for potential use in oncology and other disease areas. Medivation will gain exclusive worldwide rights for the development and commercialization of these compounds. Under the terms of the agreement, Medivation shall have access to OncoFusion's growing library of small molecule BET bromodomain inhibitor compounds from which Medivation may select compounds to move forward into drug development efforts.
OncoFusion is eligible to receive undisclosed upfront payments and potential future milestone payments subject to achievement of defined clinical and commercial milestone events. In addition, OncoFusion shall be eligible to receive royalties on the commercial sale of approved products as defined in the agreement. Further financial details were not disclosed.
"BET bromodomain proteins are emerging as an important new class of pharmacological targets with broad potential applications in oncology and other diseases," said David Hung, M.D., president and chief executive officer of Medivation. "We intend to expand our footprint in cancer by developing improved next generation therapies based upon cutting edge technologies like the one we have licensed from OncoFusion."
"This agreement with Medivation provides us with the opportunity to accelerate research and development exploring the role of BET bromodomain proteins in oncology," said Arul M. Chinnaiyan, M.D., Ph.D., co-founder of OncoFusion Therapeutics, Inc., director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at the University of Michigan Medical School. "OncoFusion is committed to discover and develop innovative and personalized medicines for oncology, and through collaborations with partners like Medivation, we can fulfill that commitment," added Shaomeng Wang, Ph.D., co-founder of OncoFusion Therapeutics, Inc. and Warner-Lambert/Parke-Davis Professor in Medicine and Director of the Center for Discovery of New Medicines at the University of Michigan.
About BET bromodomain Proteins
BET bromodomain proteins regulate gene expression and have been shown to play a critical role in cancer and other diseases. Emerging research in the area of cancer biology suggests that targeting epigenetic regulators such as the bromodomain family of proteins may reduce the growth of a number of tumor types including certain hematological and solid tumors. Recent preclinical data published in Nature(1) reported that targeting BET bromodomain proteins may have therapeutic potential in castration-resistant prostate cancer that is resistant to current treatments.
(1) Chinnaiyan, et al. Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer, Nature, DOI: 10.1038/nature13229, published online April 23, 2014.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.
About OncoFusion, Inc.
OncoFusion Therapeutics is a privately-held company, which was founded in 2012 by Arul M. Chinnaiyan, M.D., Ph.D., Shaomeng Wang, Ph.D., Kenneth J. Pienta, M.D. at the University of Michigan. OncoFusion's mission is to discover and develop the next generation of personalized therapeutics for patients with genetically defined cancers. For more information, visit www.oncofusion.com.
Forward-Looking Statement Disclaimer
The statements in this press release regarding the actions that Medivation and OncoFusion expect to take under the research and license agreement, and the potential for identifying new treatments for oncology are forward-looking statements that are subject to risks and uncertainties. Actual results may differ substantially for a number of reasons, including, but not limited to: the development of new drug compounds is a lengthy, expensive and uncertain process; the process of obtaining regulatory approval is uncertain, and may not be completed; benefits expected as a result of early studies may not materialize in later, more extensive studies; and other risks detailed under the caption "Risk Factors" in Medivation's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 27, 2014. Medivation undertakes no obligation to update these forward-looking statements other than as required by law.
Sr. Director, Investor Relations
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Aug. 25, 2016 02:00 PM EDT Reads: 3,540
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Aug. 25, 2016 01:45 PM EDT Reads: 1,351
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Aug. 25, 2016 01:00 PM EDT Reads: 3,878
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
Aug. 25, 2016 01:00 PM EDT Reads: 2,584
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
Aug. 25, 2016 12:51 PM EDT Reads: 263
Is the ongoing quest for agility in the data center forcing you to evaluate how to be a part of infrastructure automation efforts? As organizations evolve toward bimodal IT operations, they are embracing new service delivery models and leveraging virtualization to increase infrastructure agility. Therefore, the network must evolve in parallel to become equally agile. Read this essential piece of Gartner research for recommendations on achieving greater agility.
Aug. 25, 2016 12:45 PM EDT Reads: 570
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
Aug. 25, 2016 12:45 PM EDT Reads: 551
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Aug. 25, 2016 12:15 PM EDT Reads: 3,378
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
Aug. 25, 2016 11:00 AM EDT Reads: 523
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
Aug. 25, 2016 11:00 AM EDT Reads: 1,824
StarNet Communications Corp has announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 to safely tunnel the remote desktops from Linux and Unix servers to the user’s PC over encrypted SSH. Traditionally, users of PC X servers deploy the XDMCP protocol to display remote desktop environments such as the Gnome and KDE desktops on Linux servers and the CDE environment on Solaris Unix machines. XDMCP is used primarily on comp...
Aug. 25, 2016 10:30 AM EDT Reads: 479
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Aug. 25, 2016 09:15 AM EDT Reads: 591
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
Aug. 25, 2016 09:00 AM EDT Reads: 567
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Aug. 25, 2016 09:00 AM EDT Reads: 492
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Aug. 25, 2016 08:45 AM EDT Reads: 2,108